# ðŸŽ¯ PLATFORM INTEGRATION - S/P/E + SAE + LINES

---

## **SEQUENCE (S) - TUMOR SOMATIC VARIANTS**

**Input**: Tumor NGS panel results (VCF or report)  
**Process**: Evo2 scoring for SOMATIC mutations (not germline)  
**Context**: `context=tumor` flag in insights endpoints

**Key Difference**: Somatic mutations are acquired, not inherited

---

## **PATHWAY (P) - MULTI-HIT AGGREGATION**

**Sporadic Complexity**: Often multiple somatic hits across pathways

**Aggregate Across**:
- DNA repair (HRD, MMR, BER)
- Cell cycle (TP53, CDKN2A, RB1)
- Growth signaling (KRAS, PIK3CA, EGFR)
- Immune evasion (PD-L1, TMB-high)

**File**: `api/services/efficacy_orchestrator/orchestrator.py`

---

## **EVIDENCE (E) - TUMOR-BASED LITERATURE**

**Focus**:
- Somatic mutation clinical trials
- Drug approvals for somatic alterations
- NCCN guidelines for tumor genomics
- Published response rates in similar profiles

---

## **SAE FEATURES - TUMOR LANDSCAPE**

**Somatic-Specific Features**:
- `tumor_mutational_burden` (TMB) - immunotherapy candidate
- `microsatellite_instability` (MSI) - checkpoint response
- `homologous_recombination_deficiency` (HRD) - somatic PARP
- `oncogene_amplifications` (HER2, MYC, FGFR2)
- `tumor_suppressor_loss` (TP53, PTEN, RB1)

**File**: `api/services/sae_service.py`

---

## **TREATMENT LINE INTEGRATION**

**Track**: Prior therapies for cross-resistance mapping

**Compute**:
- `line_appropriateness` - standard for current line?
- `cross_resistance_risk` - overlap with failed therapies
- `sequencing_fitness` - optimal ordering

**File**: `.cursor/ayesha/treatment_lines/backend/services/treatment_line_integration.py`

---

**NEXT**: Read `04_TUMOR_NGS_INGESTION.mdc` for parsers
